A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

  • End date
    Mar 11, 2024
  • participants needed
  • sponsor
    Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Updated on 23 June 2021


This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

Condition Lennox-Gastaut Syndrome, Lennox Gastaut Syndrome
Treatment Placebo, Matching Placebo, ZX008 02 and 0.8 mg/kg/day, ZX008 0.2 and 0.8 mg/kg/day, ZX008 0.2 or 0.8 mg/kg/day
Clinical Study IdentifierNCT03355209
SponsorZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Last Modified on23 June 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note